Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of “Buy” by Analysts

Vericel Co. (NASDAQ:VCEL) has received an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $62.29.

Several research firms have recently weighed in on VCEL. Truist Financial reissued a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a research report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. BTIG Research lifted their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Canaccord Genuity Group increased their price objective on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd.

Vericel Stock Down 1.9 %

NASDAQ:VCEL opened at $46.26 on Monday. The stock has a fifty day simple moving average of $54.40 and a 200 day simple moving average of $51.72. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 771.13 and a beta of 1.78. Vericel has a 1-year low of $39.12 and a 1-year high of $63.00.

Insider Activity

In related news, CEO Dominick Colangelo sold 26,592 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now directly owns 259,997 shares of the company’s stock, valued at approximately $11,902,662.66. This trade represents a 9.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Siegal sold 3,908 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,092 shares of company stock worth $1,683,582. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Vericel by 119.3% in the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company’s stock worth $70,775,000 after purchasing an additional 701,064 shares during the period. Champlain Investment Partners LLC bought a new position in Vericel in the 4th quarter worth approximately $34,233,000. Raymond James Financial Inc. acquired a new position in shares of Vericel during the fourth quarter worth approximately $28,126,000. William Blair Investment Management LLC grew its stake in shares of Vericel by 66.3% in the fourth quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company’s stock worth $69,100,000 after acquiring an additional 501,736 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Vericel by 25.4% during the fourth quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company’s stock worth $61,630,000 after acquiring an additional 227,675 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.